Market Access News | pharmaphorum

News

Kymriah is first CAR-T cleared for follicular lymphoma in EU

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

News

AZ eyes Q3 FDA decision for Imfinzi in biliary tract cancer

The FDA has kicked off a priority review of AstraZeneca's checkpoint inhibitor Imfinzi for biliary tract cancer (BTC), setting up what could be approval for an immunotherapy for the group o

News

Idorsia is first to EU market with orexin insomnia drug

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and

News

FDA says no to two more China-developed cancer drugs

The FDA has declined to approve two more cancer therapies developed by drugmakers based in China, in what may be further evidence of a tough line taken by the regulator for drugs tested out

News

BMS bags FDA okay for cardiomyopathy drug mavacamten

Bristol-Myers Squibb's has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming a green light from the US regulator for mavacamten as a therapy for

News

Pfizer/Biohaven migraine drug rimegepant gets EU green light

Pfizer's $1.2 billion licensing deal with Biohaven for rights to oral migraine drug rimegepant is approaching a payoff after the European Commission approved the drug.

Kymriah is first CAR-T cleared for follicular lymphoma in EU

AZ eyes Q3 FDA decision for Imfinzi in biliary tract cancer

Idorsia is first to EU market with orexin insomnia drug

FDA says no to two more China-developed cancer drugs

BMS bags FDA okay for cardiomyopathy drug mavacamten

Pfizer/Biohaven migraine drug rimegepant gets EU green light

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks